Creatinolfosfate
drugOn this page
Also known as Creatinol o-phosphateCreatinolfosfatoCreatinol phosphate
Summary
Creatinolfosfate (CHEMBL2104114) is a phase-3 clinical-stage small molecule (ATC C01EB05); indicated across 2 conditions including peripheral t-cell lymphoma, not otherwise specified and cardiovascular disorder.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: C01EB05
- Indications: 2 conditions
- Chemistry: 197.13 Da · C4H12N3O4P
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2104114 |
| Name | Creatinolfosfate |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 23342 |
| ATC | C01EB05 |
| Molecular formula | C4H12N3O4P |
| Molecular weight | 197.13 |
| InChIKey | FOIPWTMKYXWFGC-UHFFFAOYSA-N |
SMILES: CN(CCOP(=O)(O)O)C(=N)N
IUPAC name: 2-[carbamimidoyl(methyl)amino]ethyl dihydrogen phosphate
Also known as: Creatinol o-phosphate, Creatinolfosfate, Creatinolfosfato, CREATINOLFOSFATE, Creatinol phosphate
Patent coverage: 81 distinct patent families (207 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| peripheral T-cell lymphoma, not otherwise specified | 3 | MONDO:0004964 | EFO:0000211 |
| cardiovascular disorder | 2 | MONDO:0004995 | EFO:0000319 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).